Japan's Otsuka Signs MOU To Invest $83 Million In Korea By 2013
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Japan's Otsuka Pharmaceuticals signed a memorandum of understanding with Korea's health ministry to invest roughly KRW100 billion ($83 million) in research and development of new drugs as well as for clinical trials over the next five years in Korea